London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The NBI is designed to track the…

Source

Previous articleMindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD
Next articleEntheon Biomedical Announces EEG Patent Application & Provides Research Update